Broc Pagni

Post-doctoral cognitive neuroscientist at NYU Langone Center for Psychedelic Medicine

Data updated

Papers

8 publications

Trials

0 clinical trials

Links

Website

Research Footprint

Broc Pagni appears in 8 tracked papers (2022–2026), most studied alongside Psilocybin, Ayahuasca and LSD, across Depressive Disorders, Anxiety Disorders and Substance Use Disorders (SUD).

Most-cited paper: Default Mode Network Modulation by Psychedelics: A Systematic Review (219 citations).

Frequent co-authors: Richard Zeifman, Daniel Perkins and Joseph Sarris.

Background & Research

Dr. Broc Pagni is a post-doctoral cognitive neuroscientist at the NYU Langone Center for Psychedelic Medicine in the lab of Dr. Michael Bogenschutz. His research focuses on identifying therapeutic psychological and neural mechanisms of psychedelic-assisted treatments, using fMRI, computational modeling, and neuropsychological testing. Before NYU, he earned a PhD in Neuroscience from Arizona State University, where he studied the neural mechanisms of mindfulness meditation in adults with autism spectrum disorder.

Key Impact

He studies the psychological and neural mechanisms of psychedelic-assisted treatments, including psilocybin for alcohol use disorder and ayahuasca-related mental health outcomes.

8

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

26 collaborators· click a node to visit their profile

Full network →

Compounds

PsilocybinAyahuascaLSDMDMA

Topics

Depressive DisordersAnxiety DisordersSubstance Use Disorders (SUD)Personality & Trait FactorsInterpersonal Functioning & Social ConnectednessNeuroimaging & Brain MeasuresAlcohol Use Disorder (AUD)Public Health, Prevention & Behaviour ChangeObsessive-Compulsive Disorder (OCD)PTSDSchizophreniaNeurocognitive DisordersHealthy VolunteersSuicidalityPersonality Disorders

Top Collaborators

Affiliations

Institutions, companies, and organisations Broc Pagni is associated with.

NYU Langone Health

Home to the NYU Langone Center for Psychedelic Medicine, one of the world's leading academic institutions in psychedelic research. Has conducted landmark psilocybin trials for smoking cessation, alcohol use disorder, and depression in cancer patients, spearheaded by Dr. Michael Bogenschutz and colleagues.

View stakeholder →

NYU Grossman School of Medicine

NYU Grossman School of Medicine is New York University's medical school and a core academic unit of NYU Langone Health. It provides MD and other medical education, conducts biomedical research, and delivers clinical care in the United States.

View stakeholder →